Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
On Tuesday, Piper Sandler reaffirmed its confidence in The Cooper Companies (NASDAQ:COO), upholding an Overweight stock rating and a price target of $115.00. The medical device company, currently valued at $16.1 billion, has maintained profitability with a healthy 67% gross margin. According to InvestingPro analysis, the stock trades at a relatively high P/E ratio of 38.6x, though analysts remain optimistic with price targets ranging from $90 to $120. The firm’s analysts have closely examined the U.S. contact lens market, engaging with a distributor to gauge the current state of demand and supply amidst recent uncertainties. These concerns arose from tariff negotiations since Liberation Day and the observation of weaker first-quarter results from Cooper’s industry peers.
The distributor’s feedback suggests that consumer demand for contact lenses has remained stable, with consistent order quantities and product mix. Additionally, the supply chain for contact lenses appears to be functioning effectively, although it remains an area to be watched, similar to other medical technology categories. This stability is reflected in Cooper’s financial performance, with revenue growing at 7.15% over the last twelve months and the company maintaining a strong financial health score of "GOOD" according to InvestingPro’s comprehensive analysis.
Price increases are anticipated in the sector due to the tariffs, with industry leader Johnson & Johnson expected to raise average selling prices (ASPs) in the upcoming month. Despite a slowdown in growth for Cooper’s competitors in the first quarter, Piper Sandler anticipates an improvement for Cooper’s second quarter, projecting that CooperVision’s (CVI) growth will accelerate to 7%.
The analyst’s remarks come ahead of The Cooper Companies’ second-quarter earnings report, which is scheduled for release on Thursday. Piper Sandler’s position remains bullish, reiterating the Overweight rating and maintaining the $115 price target. For deeper insights into Cooper Companies’ valuation metrics, growth potential, and comprehensive financial analysis, investors can access the detailed Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Cooper Companies announced its first quarter fiscal year 2025 results, revealing a slight revenue shortfall with $965 million reported against an anticipated $978 million. Despite this, the company exceeded earnings per share (EPS) estimates by one cent, posting an adjusted EPS of $0.92. Stifel analysts revised their price target for Cooper Companies to $105, maintaining a Buy rating, while Piper Sandler adjusted its target to $115, retaining an Overweight rating. Both firms noted the company’s robust gross margin performance, though revenue growth challenges were highlighted, particularly in the CooperVision segment in Asia-Pacific and CooperSurgical’s fertility business.
Needham reaffirmed its Hold rating, pointing out that the revenue miss was largely due to weak sales in specific segments, but noted potential for stronger performance in the latter half of the fiscal year. In governance news, Cooper Companies appointed Barbara Carbone as an independent director to its Board, enhancing its audit and financial oversight capabilities. Additionally, shareholders approved key proposals at the Annual Meeting, including the election of seven directors and the ratification of KPMG LLP as the independent auditor. The company’s guidance remains unchanged, with analysts suggesting potential upside from foreign exchange considerations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.